Loading...
NPI 1366193088 · Coppell, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Biodx Labs is a clinical medical laboratory provider located in Coppell, Texas. This profile covers 2 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Biodx Labs |
| Address | 670 N Macarthur Blvd Ste 160 |
| City | Coppell |
| State | TX |
| ZIP | 75019 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 13, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $15.1M |
| Medicaid | $1.9M |
BIODX LABS operates as a high-volume molecular diagnostic laboratory focused on SARS-CoV-2 respiratory testing and viral genotyping: its top Medicare codes are 87637 (multiplex SARS–CoV-2/flu/RSV amplified nucleic acid probe) and 87913 (NGS genotype analysis for SARS–CoV–2), reflecting both high-throughput respiratory pathogen screening and next-generation sequencing capabilities. The presence of large claim counts for these codes (87637: 84.5K Medicare claims; 87913: 13.1K Medicare claims) supports an operational model centered on centralized lab testing rather than low-volume pathology services.
Medicare revenue is highly concentrated in a very small code set: the precomputed top-3 Medicare codes account for 100.0% of the provider's Medicare revenue, with 87637 representing $11.8M (78.2% of Medicare revenue) and 87913 representing $3.3M (21.8% of Medicare revenue). This indicates nearly all Medicare billing is driven by multiplex respiratory testing and SARS‑CoV‑2 genotyping services.
Medicaid billing is similarly concentrated: the precomputed top-3 Medicaid codes account for 99.9% of Medicaid revenue, with 87913 contributing $1.4M (73.9% of Medicaid revenue) and 87637 contributing $503K (26.0% of Medicaid revenue). The Medicaid mix shows the same two service lines dominate state-level revenue, with U0004 and other codes making only negligible contributions.
BIODX LABS is effectively Medicare‑dominant on scale: reported lifetime Medicare revenue is $15.1M versus $1.9M in Medicaid revenue, so Medicare represents the vast majority of the payer mix. That disparity suggests operations and contracting are heavily oriented toward Medicare volume and reimbursement patterns rather than Medicaid.
Competitive standing for 87637 on Medicare is exceptional: the provider ranks #2 of 1141 nationally (100th percentile) and is described as an "extreme outlier, far above typical national volume for this code," making it a national leader in multiplex respiratory testing throughput. By contrast, 87913 on Medicare ranks #4 of 11 nationally (70th percentile) and is labeled "typical, unremarkable volume for this code," indicating the provider is a major national outlier for screening volume but only a modest participant in the smaller NGS genotyping peer group.
State-level competitive signals are mixed: for Medicaid 87637 the provider ranks #4 of 122 in-state (98th percentile), indicating a very strong position among Texas peers for multiplex respiratory testing, while Medicaid 87913 ranks #4 of 6 in-state (40th percentile) and is characterized as "typical, unremarkable volume for this code," showing more modest state-level NGS genotyping presence. These differences suggest dominance in high-throughput screening within the state but limited leadership in genotyping among the smaller set of in-state NGS providers.
Payment and utilization patterns show payer-level pricing differences alongside high claim volumes: Medicare average paid/claim for 87637 is $140 versus $52 for Medicaid, and for 87913 Medicare average paid/claim is $252 versus $205 for Medicaid. Combined with the claim counts (Medicare 87637: 84.5K; Medicare 87913: 13.1K; Medicaid 87913: 7K; Medicaid 87637: 9.7K), this indicates materially higher Medicare revenue per claim and much larger Medicare throughput driving the overall revenue gap.
The provider's NPI was enumerated 2022-01-13 (~4 years ago), so the organization has achieved substantial Medicare scale in a relatively short operating window. Such rapid scaling to $15.1M in Medicare revenue, concentrated in a narrow set of codes, signals a focused laboratory build-out around COVID-era high-throughput testing and sequencing services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 84,540 | $140 | $11.8M |
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 13,090 | $250 | $3.3M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 6,970 | $210 | $1.4M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 9,670 | $50 | $503K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 60 | $20 | $1.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 60 | $10 | $510 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 60 | $10 | $510 |
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87913 | Code 87913 describes genotype analysis using a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next–generation sequencing… | 4 | 10 | 8,000 | $200 | $1.5M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 4 | 120 | 340 | $120 | $422K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 84 | 100 | 470 | $50 | $319.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 212 | 260 | 640 | $20 | $137.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 231 | 340 | 220 | $10 | $24.1K |
Other providers in the same ZIP code as Biodx Labs, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Fifty 50 Medical LLC | TX | Durable Medical Equipment & Medical Supplies | $0 | $54.7M |
| Inform Diagnostics, Inc. | TX | Anatomic Pathology & Clinical Pathology Physician | $10.9M | $15.9M |
| Sterling Ems, LLC | TX | Ambulance | $587.6K | $1.3M |
| Pathologists Bio-medical Laboratories PLLC | TX | Clinical Medical Laboratory | $1.1M | $80K |
| Lavanya Boddu | TX | Emergency Medicine Physician | $41.9K | $511.6K |
| Steven Swaldi | TX | Family Medicine Physician | $122.8K | $0 |
| Diana Coxsey | TX | Family Medicine Physician | $79.2K | $0 |
| Priyanka Chaudhry | TX | Neurology Physician | $23.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.